REQUEST # 0323860

Biomimetic technology to improve intestinal absorption of

biomacromolecule
MANAGER: Y. Kamiyama

RESPONSE DUE DATE: November 29, 2016

SOLUTION PROVIDER HELP DESK

EMAIL: PhD2@ninesigma.com

Opportunity
Joint research/development, contract research/development,
technology licensing

PHONE: +1-216-283-3901

Timeline
Start of clinical study (within 3 years)

Financials
Negotiable
(Details to be negotiated based on the contents of the proposal;
Licensing fees to be discussed separately)

REQUEST FOR PROPOSAL DESCRIPTION

NineSigma, representing a leading
pharmaceutical company, seeks a technology
that can improve intestinal absorption of
poorly absorbable biomacromolecule using a
biomimetic approach.
The client aims to commercialize
biomacromolecule with extremely poor
gastrointestinal absorption, including proteins and
nucleic acids, as oral formulations. The client has
therefore issued this open request in order to
achieve the early practical use by collaborating
with potential organizations possessing innovative
technologies.
Requirements
Targeted biomacromolecules: Proteins,
nucleic acids
Molecular weight: 100 kDa or more (in the
case of proteins)
Administration route: Oral
Anticipated approaches
The following biomimetic approaches with low
biotoxicity are anticipated:
Enhanced intestinal retention

Mimicking the mechanism of intestinal

retention associated with adhesion of bacteria
to the intestinal mucosal epithelium
Avoidance of gut barrier
Mimicking the mechanism of white blood cells
migration to blood vessel
Mimicking the mechanism of transcytosis of
bacteria or immunoglobulin by
immunocompetent cells and intestinal
epithelial cells
Proposals including innovative biomimetic
approaches other than those described above
are also welcome.
Requirements for the proposed technology
The proposed technology should meet the
following requirements:
The validity of the technology needs to have
been verified in in vitro study, and preferably
in in vivo study.
A sufficient amount of drug should be
absorbed from the gastrointestinal tract, the
bioactivity of drug after absorption should not
be affected, and an active effect should be
exerted in targeted tissues.

Offices: Cleveland - USA, Tokyo - Japan, Leuven Belgium, Melbourne Australia, Seoul South Korea
RFP format and graphics Copyright 2016 NineSigma, Inc

NineSigma Request # 0323860

Biomimetic technology to improve intestinal absorption of biomacromolecule

A non-invasive approach should be used.

- No risk of enterocleisis or tissue damage
APPROACHES NOT OF INTEREST
The following approaches are excluded from this
open request:
Technology or material that uses a substance
harmful to human body
Technology involving tissue damage, such as
the destruction of tight junction
Approach involving modification and alteration
of a drugs chemical structure
ANTICIPATED PROJECT PHASES OR PROJECT PLAN
The proposing organization is required to submit
proposals using the attached Response Template.
The client will review proposals and select suitable
candidates for collaboration. Once candidates are
selected, the client will execute confidential
disclosure agreements (CDAs) in order to seek
further information disclosure and discuss possible
research approaches.
Once the best candidates have been determined,
the client will execute joint research agreements
with partners.

Past research achievements (patents,

research papers, research presentations,
etc.)
SUBMITTING A RESPONSE
All proposals should be submitted online at
NineSights, the NineSigma open innovation
community, according to the instructions in the
Proposal Template. Supplemental files may be
submitted in addition to the proposal document.
For assistance, please contact the Solution
Provider Help Desk (PhD2@ninesigma.com).
REQUEST GUIDELINES
Non-Confidential Disclosure
By submitting a response you represent that the response
does not and will not be deemed to contain any
confidential information of any kind whatsoever.

Response Evaluation
NineSigmas client will evaluate the response using the
following criteria:

ITEMS TO BE INCLUDED IN THE PROPOSAL

Responses will use the Proposal Template which
is linked to the attachments shown at the bottom
of the link <REQ0323860> and include the
following items:
Overview of the proposed technology
(background of technology development,
assumed application for the development,
uniqueness, etc.)
Mechanism to promote the efficient intestinal
absorption of biomacromolecules
Experimental data supporting the above
mechanism (track record of evaluated drugs,
results of in vivo studies, etc.)
Considerations on the safety
Current R&D stage
Research and development plans to meet the
ultimate technical requirements, and what is
particularly needed for the realization.
Any requests concerning the collaboration form
Contacts and license agreements with other
companies
Current status of intellectual property related to
the proposed technology

NineSigma, Inc.

Page 2

Overall scientific and technical merit of the proposed

approach
Approach to proof of concept or performance
Potential for proprietary position (i.e., is the
technology novel or protectable)
Economic potential of concept
Respondents capabilities and related experience

Realism of the proposed plan and cost estimates

Response Selection
By submitting a response, you acknowledge that
NineSigmas client reserves the sole and absolute right
and discretion to select for award all, some, or none of the
responses received for this announcement. NineSigmas
client also may choose to select only specific tasks within a
proposal for award. NineSigma's client has the sole and
absolute discretion to determine all award amounts.
NineSigma will contact respondents with highly responsive
proposals for next steps, or the client may contact
respondents directly.

NineSights.com